CERo Therapeutics Holdings, Inc. (CERO)
(Delayed Data from NSDQ)
$7.96 USD
-0.15 (-1.79%)
Updated Aug 8, 2025 03:59 PM ET
After-Market: $7.96 +0.01 (0.06%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CERO 7.96 -0.15(-1.79%)
Will CERO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CERO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CERO
CERO Maintains Buy Rating with $30 Target Price by D. Boral Capital | CERO Stock News
CERO Advances in Clinical Trial for Acute Myeloid Leukemia Treatment
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 | CERO Stock News
Cero Therapeutics doses second patient in Phase 1 CER-1236 trial
CERO Stock Offering Proceeds Not Benefiting the Company | CERO Stock News